Bayer Learns Valuable Risk Management Lessons from Lawsuit

We take a look into the Bayer product claims and how legal action has led to lessons learned by the company as it develops a risk management strategy

Bayer has provided insight into some important measures that it will take to mitigate future risks, following a lawsuit that disallowed the company’s settlement amount. Allegations were made into the Roundup weedkiller, which claimed that the product causes cancer. 

In response to the allegations, Bayer offered a US$2bn settlement for the claims, which was denied by Judge Vince Chhabria, US District Court. After such serious allegations, the company has responded with its five measures to limit any legal issues regarding its products. 

Customer Transparency 

Providing knowledge to customers and transparency around all certification is what Bayer plans to achieve through its website creation. A website will be set up and made publicly accessible, which contains all scientific details for its products, and label contents will be available online. The company will also push to gain EPA approval of the language used on the Roundup labels. 

Domestic Market

The company will begin discussions regarding the use of glyphosate-based products in the residential market. The ‘overwhelming’ number of claims were related to the Roundup Lawn and Garden range, which is aimed at domestic use. Bayer will not discontinue the use of glyphosate-based products in its professional and agricultural products. However, its suitability for domestic use will be discussed. 

Expert Advisory Panel

Products that consist of chemical compositions require a specific level of expertise. Bayer will take on a dedicated advisory panel composed of external scientific experts. The aim of the panel is to continually investigate potential areas that may contribute to legal action.

Ongoing Claim Assessment

Bayer stated it has received approximately 96,000 claims in total but has also announced a resolution to all of these claims. The company will take into account any further discussions regarding existing claims as part of its attempt to show “good faith to bring an end to litigation and liability risk.” It will also assess this strategy regularly to determine whether it aligns with the company’s best interests. The current appeals will continue through the legal process, as Bayer believes this will be beneficial for the company’s ongoing risk mitigation strategy. 

For more risk management insights, check out Procurement magazine.


Featured Articles

How Ivalua and Visa Will Unlock Capital within Supply Chains

Ivalua and Visa join forces to create new efficiency in spend management offering secure and efficient payment solutions via the cloud

AWS Marketplace: Streamlining Software Solutions

AWS Marketplace simplifies procurement for public sector organisations, offers compliance support & prevents vendor lock-in, revolutionising cloud services

Keith Hartley, LevaData CEO, on Philosophy and Procurement

Keith Hartley, CEO at LevaData, discusses how the first principles philosophy and design thinking can revolutionise procurement processes

Mars Snacking's Amanda Davies joins P&SC LIVE New York


Coupa Software’s Mike Schanker joins P&SC LIVE New York

Procurement Strategy

ServiceNow’s Kirsten Loegering joins P&SC LIVE New York

Supply Chain Management